R
R&G PharmaStudies Co Ltd
SZSE:301333
R&G PharmaStudies Co Ltd
SZSE:301333
Price:
75.68
CNY
-3.06%
Market Cap:
¥7.3B
Income Statement
Earnings Waterfall
R&G PharmaStudies Co Ltd
R&G PharmaStudies Co Ltd
Income Statement
R&G PharmaStudies Co Ltd
R&G PharmaStudies Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
3
|
4
|
0
|
0
|
|
| Revenue |
608
N/A
|
635
+4%
|
640
+1%
|
634
-1%
|
638
+1%
|
628
-1%
|
493
-22%
|
721
+46%
|
537
-26%
|
738
+38%
|
759
+3%
|
744
-2%
|
740
-1%
|
745
+1%
|
789
+6%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(375)
|
(393)
|
(401)
|
(400)
|
(403)
|
(401)
|
(316)
|
(434)
|
(330)
|
(447)
|
(461)
|
(468)
|
(471)
|
(482)
|
(521)
|
|
| Gross Profit |
233
N/A
|
242
+4%
|
239
-1%
|
235
-2%
|
235
+0%
|
227
-3%
|
177
-22%
|
287
+62%
|
207
-28%
|
291
+41%
|
298
+2%
|
276
-7%
|
269
-3%
|
262
-2%
|
268
+2%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(121)
|
(125)
|
(121)
|
(121)
|
(127)
|
(123)
|
(89)
|
(144)
|
(122)
|
(172)
|
(193)
|
(151)
|
(141)
|
(131)
|
(126)
|
|
| Selling, General & Administrative |
(81)
|
(83)
|
(78)
|
(77)
|
(80)
|
(81)
|
(61)
|
(102)
|
(86)
|
(120)
|
(134)
|
(98)
|
(89)
|
(82)
|
(73)
|
|
| Research & Development |
(40)
|
(44)
|
(46)
|
(48)
|
(49)
|
(51)
|
(41)
|
(51)
|
(41)
|
(55)
|
(56)
|
(55)
|
(57)
|
(59)
|
(60)
|
|
| Depreciation & Amortization |
(3)
|
(1)
|
(1)
|
0
|
(3)
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
3
|
3
|
5
|
5
|
5
|
9
|
13
|
12
|
6
|
4
|
(3)
|
6
|
6
|
10
|
7
|
|
| Operating Income |
112
N/A
|
116
+4%
|
118
+2%
|
113
-4%
|
108
-5%
|
104
-4%
|
88
-15%
|
143
+62%
|
85
-40%
|
119
+39%
|
104
-12%
|
125
+20%
|
128
+2%
|
131
+2%
|
142
+9%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
1
|
2
|
9
|
16
|
21
|
27
|
23
|
39
|
26
|
36
|
33
|
33
|
32
|
27
|
28
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
114
N/A
|
118
+4%
|
127
+8%
|
129
+2%
|
129
0%
|
130
+1%
|
111
-15%
|
182
+65%
|
111
-39%
|
155
+39%
|
137
-12%
|
158
+16%
|
160
+1%
|
158
-1%
|
170
+8%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
(13)
|
(14)
|
(15)
|
(15)
|
(15)
|
(15)
|
(12)
|
(20)
|
(11)
|
(19)
|
(14)
|
(16)
|
(15)
|
(14)
|
(18)
|
|
| Income from Continuing Operations |
100
|
104
|
112
|
114
|
114
|
116
|
98
|
163
|
100
|
136
|
122
|
142
|
145
|
144
|
153
|
|
| Income to Minority Interest |
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
|
| Net Income (Common) |
99
N/A
|
103
+4%
|
110
+7%
|
112
+2%
|
114
+1%
|
116
+2%
|
98
-15%
|
163
+65%
|
100
-39%
|
135
+36%
|
121
-10%
|
140
+16%
|
143
+2%
|
143
0%
|
151
+6%
|
|
| EPS (Diluted) |
1.03
N/A
|
1.71
+66%
|
3.67
+115%
|
1.87
-49%
|
1.18
-37%
|
1.92
+63%
|
1.02
-47%
|
1.69
+66%
|
1.04
-38%
|
1.41
+36%
|
1.26
-11%
|
1.47
+17%
|
1.51
+3%
|
1.51
N/A
|
1.6
+6%
|
|
Switch to:
Switch to:
See Also
Discover More
